CompletedISRCTN68824876
Amisulpride Added for Schizophrenia Symptoms Despite Clozapine
About this title
Read the official source — ISRCTN68824876Interventional studyAges 18–65United Kingdom
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- London and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 69
- Sponsor
- Imperial College London
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United Kingdom
- Age range
- From 18 Years to 65 Years
- Official registry ID
- ISRCTN68824876
- Official title
Show the full official title
Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedLondon · Manchester
Questions about this study
Who is behind this study?
The study sponsor is Imperial College London, a university.
Did this study involve medication?
Yes. The study involved medication, including Amisulpride and placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
Long-Term Safety of EVP-6124 Added to Schizophrenia Medication